SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Lecanemab

            Therapeutic Area: Neurology Product Name: BAN2401

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eisai

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 21, 2021

            Details:

            The presentations will include the latest data of the investigational anti-amyloid beta (Aβ) protofibril selective antibody lecanemab (BAN2401) for which the FDA has granted Breakthrough Therapy designation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Isoflurane

            Therapeutic Area: Neurology Product Name: Sedaconda

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 20, 2021

            Details:

            The topline results, announced in July 2020, showed that the study reached its primary goal; to show that Sedaconda administered via AnaConDa is an effective sedation method for ventilated ICU patients, comparable to propofol.